ELVN
Enliven Therapeutics, Inc.
1W: +4.5%
1M: +10.9%
3M: +81.2%
YTD: +86.7%
1Y: +38.9%
3Y: +36.3%
5Y: -33.5%
$29.03
-1.02 (-3.39%)
After Hours: $28.45 (-0.58, -2.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$35.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.7B
52W Range13.3-30.98
Volume778,176
Avg Volume1,023,461
Beta1.06
Dividend—
Analyst Ratings
Company Info
CEORichard A. Fair
Employees62
SectorHealthcare
IndustryBiotechnology
IPO Date2020-03-12
Websiteenliventherapeutics.com
6200 Lookout Road
Boulder, CO 80301
US
Boulder, CO 80301
US
720 647 8519
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Latest News
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
Enliven Therapeutics: Q4 Earnings Insights
Enliven Therapeutics GAAP EPS of -$0.48 misses by $0.09
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Collins Helen Louise | M-Exempt | 5,000 | $2.48 | 2026-03-17 |
| Collins Helen Louise | S-Sale | 5,000 | $27.76 | 2026-03-17 |
| Collins Helen Louise | M-Exempt | 5,000 | $2.48 | 2026-03-17 |
| Collins Helen Louise | M-Exempt | 10,129 | $2.48 | 2026-03-10 |
| Collins Helen Louise | S-Sale | 10,129 | $30.19 | 2026-03-10 |